share_log

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3：募資說明書
美股SEC公告 ·  08/14 12:43

Moomoo AI 已提取核心訊息

Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in a previous prospectus dated March 23, 2023, with details from its quarterly report filed on August 13, 2024. The supplement relates to the issuance of 4,776,038 shares of common stock underlying previously issued warrants. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' with a last reported sales price of $0.35 per share as of August 12, 2024. The supplement, which includes the attached Quarterly Report, provides updated financial information and should be read in conjunction with the original prospectus. The Quarterly Report details the company's financial position, including a net loss of $14.3 million for the six months ended June 30, 2024, and a working capital deficit of $16.0 million. The company has incurred losses of $139.8 million since its inception and continues to face a high degree of risk. The report also includes unaudited condensed consolidated financial statements and notes, which outline the company's assets, liabilities, stockholders' deficit, and comprehensive loss for the period.
Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in a previous prospectus dated March 23, 2023, with details from its quarterly report filed on August 13, 2024. The supplement relates to the issuance of 4,776,038 shares of common stock underlying previously issued warrants. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' with a last reported sales price of $0.35 per share as of August 12, 2024. The supplement, which includes the attached Quarterly Report, provides updated financial information and should be read in conjunction with the original prospectus. The Quarterly Report details the company's financial position, including a net loss of $14.3 million for the six months ended June 30, 2024, and a working capital deficit of $16.0 million. The company has incurred losses of $139.8 million since its inception and continues to face a high degree of risk. The report also includes unaudited condensed consolidated financial statements and notes, which outline the company's assets, liabilities, stockholders' deficit, and comprehensive loss for the period.
Panbela Therapeutics，Inc.於2024年8月13日提交了招股說明書補充，更新並補充了先前於2023年3月23日的招股說明書中的信息，包含2024年8月13日提交的季度報告中的細節。此補充涉及發行4776038股普通股，以替代以前發行的認股權證。公司的普通股在OTCQb上以「PBLA」爲標的，截至2024年8月12日，最後報價爲每股0.35美元。包括附加的季度報告在內的補充說明提供了更新的財務信息，應與原始招股說明書一起閱讀。季度報告詳細說明了公司的財務狀況，包括截至2024年6月30日的六個月淨虧損1430萬美元和運營資本赤字1600萬美元。自成立以來，公司已經虧損了13980萬美元，並繼續面臨高度風險。報告還包括未經審計的簡明合併財務報表和說明，概述了公司的資產、負債、股東權益及本期綜合虧損。
Panbela Therapeutics，Inc.於2024年8月13日提交了招股說明書補充，更新並補充了先前於2023年3月23日的招股說明書中的信息，包含2024年8月13日提交的季度報告中的細節。此補充涉及發行4776038股普通股，以替代以前發行的認股權證。公司的普通股在OTCQb上以「PBLA」爲標的，截至2024年8月12日，最後報價爲每股0.35美元。包括附加的季度報告在內的補充說明提供了更新的財務信息，應與原始招股說明書一起閱讀。季度報告詳細說明了公司的財務狀況，包括截至2024年6月30日的六個月淨虧損1430萬美元和運營資本赤字1600萬美元。自成立以來，公司已經虧損了13980萬美元，並繼續面臨高度風險。報告還包括未經審計的簡明合併財務報表和說明，概述了公司的資產、負債、股東權益及本期綜合虧損。
有用
沒用

該公告為獨立文件：

獨立文件1

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間